Literature DB >> 22045968

Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial.

G B John Mancini1, Pamela M Hartigan, Eric R Bates, Steven P Sedlis, David J Maron, John A Spertus, Daniel S Berman, William J Kostuk, Leslee J Shaw, William S Weintraub, Koon K Teo, Marcin Dada, Bernard R Chaitman, Robert A O'Rourke, William E Boden.   

Abstract

BACKGROUND: The extent to which recurrent events in patients with stable coronary artery disease is attributable to progression of an index lesion originally ≥50% diameter stenosis (DS) but not revascularized or originally <50% DS is unknown during optimal medical therapy (OMT). METHODS AND
RESULTS: In the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial, 205 patients assigned to OMT plus percutaneous coronary intervention (PCI) and 284 patients assigned to OMT only had symptom-driven angiograms suitable for analysis. Percentages of patients in the OMT+PCI and OMT-only cohorts with index lesions originally <50% DS were 30% and 32%, respectively; 20% and 68% had index lesions originally ≥50% DS. In both groups, index lesions originally <50% or ≥50% DS represented <4% and <25% of all such lesions, respectively. The only angiographic predictor of myocardial infarction or acute coronary syndrome was the number of lesions originally ≥50% DS that had not been revascularized (odds ratio, 1.15; confidence limits, 1.01-1.31; P<0.04).
CONCLUSIONS: Lesions originally <50% DS were index lesions in one third of patients referred for symptom-driven repeat angiography, but represented <4% of all such lesions. Nonrevascularized lesions originally ≥50% DS were more often index lesions in OMT-only patients, but still represented a minority (<25%) of all such lesions. These findings underscore the need for improved therapies to arrest plaque progression and reliable strategies for selecting stenoses warranting PCI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22045968     DOI: 10.1161/CIRCINTERVENTIONS.110.960062

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  9 in total

Review 1.  Effect of Percutaneous Coronary Intervention on Survival in Patients with Stable Ischemic Heart Disease.

Authors:  Francisco Ujueta; Ephraim N Weiss; Binita Shah; Steven P Sedlis
Journal:  Curr Cardiol Rep       Date:  2017-02       Impact factor: 2.931

2.  High-grade culprit lesions are a common cause of ST-segment elevation myocardial infarction.

Authors:  Michael Liang; Takashi Kajiya; Mark Y Chan; Edgar Tay; Chi-Hang Lee; Arthur Mark Richards; Adrian F Low; Huay Cheem Tan
Journal:  Singapore Med J       Date:  2015-06       Impact factor: 1.858

3.  Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial.

Authors:  Maros Ferencik; Thomas Mayrhofer; Daniel O Bittner; Hamed Emami; Stefan B Puchner; Michael T Lu; Nandini M Meyersohn; Alexander V Ivanov; Elizabeth C Adami; Manesh R Patel; Daniel B Mark; James E Udelson; Kerry L Lee; Pamela S Douglas; Udo Hoffmann
Journal:  JAMA Cardiol       Date:  2018-02-01       Impact factor: 14.676

4.  Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain).

Authors:  Udo Hoffmann; Maros Ferencik; James E Udelson; Michael H Picard; Quynh A Truong; Manesh R Patel; Megan Huang; Michael Pencina; Daniel B Mark; John F Heitner; Christopher B Fordyce; Patricia A Pellikka; Jean-Claude Tardif; Matthew Budoff; George Nahhas; Benjamin Chow; Andrzej S Kosinski; Kerry L Lee; Pamela S Douglas
Journal:  Circulation       Date:  2017-04-07       Impact factor: 29.690

5.  Factors Associated With Coronary Artery Disease Progression Assessed By Serial Coronary Computed Tomography Angiography.

Authors:  Gabriel Cordeiro Camargo; Tamara Rothstein; Maria Eduarda Derenne; Leticia Sabioni; João A C Lima; Ronaldo de Souza Leão Lima; Ilan Gottlieb
Journal:  Arq Bras Cardiol       Date:  2017-05-04       Impact factor: 2.000

6.  Flow Mediated Dilatation and Progression of Abdominal Aortic Aneurysms.

Authors:  R Lee; K Bellamkonda; A Jones; N Killough; F Woodgate; M Williams; I Cassimjee; A Handa
Journal:  Eur J Vasc Endovasc Surg       Date:  2017-04-14       Impact factor: 7.069

7.  Quantitative plaque characterisation and association with acute coronary syndrome on medium to long term follow up: insights from computed tomography coronary angiography.

Authors:  Ravi K Munnur; Kevin Cheng; Jordan Laggoune; Andrew Talman; Rahul Muthalaly; Nitesh Nerlekar; Yi-Wei Baey; Jason Nogic; Andrew Lin; James D Cameron; Sujith Seneviratne; Dennis T L Wong
Journal:  Cardiovasc Diagn Ther       Date:  2022-08

8.  Risk factor reduction in progression of angiographic coronary artery disease.

Authors:  Hoang M Lai; Wilbert S Aronow; Anthony D Mercando; Phoenix Kalen; Harit V Desai; Kaushang Gandhi; Mala Sharma; Harshad Amin; Trung M Lai
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

Review 9.  Flow Mediated Dilatation as a Biomarker in Vascular Surgery Research.

Authors:  Kirthi Bellamkonda; Matthew Williams; Ashok Handa; Regent Lee
Journal:  J Atheroscler Thromb       Date:  2017-07-01       Impact factor: 4.928

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.